10-Q: Avid Bioservices Reports Q3 Loss Amidst Revenue Decline and Debt Restructuring

Avid Bioservices reported a net loss for the third quarter of fiscal year 2024, driven by decreased revenue and increased costs, while also addressing a debt default through a new convertible note offering.

Summary

• Avid Bioservices reported a net loss of $6.0 million for the third quarter of fiscal year 2024, compared to a net loss of $0.2 million in the same period last year.
• The company's revenue decreased by 11% to $33.8 million, primarily due to lower manufacturing and process development revenues.
• Gross profit significantly declined to $2.4 million, with a gross margin of 7%, compared to $9.8 million and 26% respectively in the prior year.
• Operating expenses decreased slightly to $6.4 million, but the company still reported an operating loss of $4.0 million.
• The company experienced a $2.2 million loss in other income and expenses, primarily due to an unrealized loss from an investment in an equity security.
• A material weakness was identified in internal controls over financial reporting related to debt and interest accounting.
• The company addressed a debt default by issuing $160 million in new convertible senior notes due 2029 and repurchasing the 2026 notes.
• The company's backlog increased to $206 million as of January 31, 2024, compared to $176 million at the end of the same quarter in fiscal 2023.

Sentiment

Score: 3

Explanation: The document indicates a negative sentiment due to the significant decrease in revenue and gross profit, the net loss, and the identification of a material weakness in internal controls. While the company addressed its debt issues and expanded its facilities, the overall financial performance is concerning.

Positives

• The company's backlog increased to $206 million, indicating future revenue potential.
• Avid Bioservices successfully completed its cell and gene therapy facility, expanding its service offerings.
• The company addressed a debt default by issuing new convertible notes and repurchasing the existing debt.

Negatives

• The company reported a net loss of $6.0 million for the quarter.
• Revenue decreased by 11% year-over-year.
• Gross profit margin significantly declined to 7%.
• A material weakness in internal control over financial reporting was identified.
• The company experienced a $2.2 million loss in other income and expenses.

Risks

• The company's financial performance is subject to fluctuations in manufacturing runs and process development services.
• The company's ability to raise additional capital is dependent on market conditions and demand for its stock.
• The company's backlog is subject to risks such as customer cancellations, delays, and project execution issues.
• The company identified a material weakness in internal control over financial reporting related to debt and interest accounting.
• The company's debt obligations could impact its financial flexibility.

Future Outlook

The company believes that its existing cash and cash equivalents, along with anticipated cash flows from operations, will be sufficient to fund operations for at least the next 12 months. The company may also draw on its revolving credit facility or seek additional financing if needed.

Management Comments

• Management is focused on aligning with the growth of the biopharmaceutical drug substance contract services market.
• Management aims to invest in additional manufacturing capacity and capabilities.
• Management seeks to broaden market awareness and expand the customer base.
• Management is exploring strategic opportunities to enhance capabilities.
• Management intends to increase the operating profit margin to best-in-class within the industry.

Industry Context

The company operates in the competitive CDMO market, which is experiencing growth due to the increasing demand for biologics manufacturing. The company's expansion into cell and gene therapy aligns with current industry trends, but it faces challenges in maintaining profitability and managing debt.

Comparison to Industry Standards

• Avid's gross margin of 7% is significantly below the industry average for CDMOs, which typically ranges from 20% to 40%.
• Companies like Catalent and Lonza, which are major players in the CDMO space, generally report higher gross margins and more stable revenue streams.
• The company's debt restructuring is similar to actions taken by other smaller CDMOs facing financial challenges, but the new debt increases the company's financial risk.
• The completion of the cell and gene therapy facility is a positive step, but it will take time to generate significant revenue and compete with established players in this market.

Corporate Governance

Stakeholder Impact

• Shareholders are negatively impacted by the net loss and the decrease in gross profit.
• Employees may be impacted by the company's financial performance and any potential cost-cutting measures.
• Customers may be impacted by the company's ability to deliver services due to financial constraints.
• Creditors are impacted by the company's debt restructuring and its ability to meet its obligations.

Next Steps

• The company will focus on integrating the new cell and gene therapy facility into its operations.
• The company will need to improve its financial performance to meet its debt obligations.
• The company will need to remediate the material weakness in internal controls over financial reporting.

Key Dates

Keywords

CDMO, contract manufacturing, biologics, cell and gene therapy, convertible notes, debt, revenue, gross profit, financial results, backlog